Tags: Heart Disease | Deadly Cholesterol Condition Drug Kynamro

New Help for Deadly Cholesterol Condition

Thursday, 07 Mar 2013 10:37 AM

Kynamro (mipomersen sodium) has been approved by the U.S. Food and Drug Administration to treat a rare inherited condition in which the body can't remove low-density lipoprotein (LDL) cholesterol from the blood.
 
LDL is the so-called "bad" cholesterol that can clog the arteries and cause heart attack and stroke. Many people with homozygous familial hypercholesterolemia (HoFH) have a heart attack and die before age 30, the FDA said in a news release.
 
HoFH affects approximately one of every 1 million people in the United States. Kynamro is a once-weekly injection designed to lower creation of blood lipid particles that ultimately form LDL, the agency said.
 
Clinical studies showed Kynamro lowers LDL levels an average of about 25 percent in the first 26 weeks of use, the FDA said. The drug will carry a "black box" label warning of possible liver abnormalities that could lead to progressive liver disease.
 
More common side effects noted during clinical testing included injection-site reactions, flu-like symptoms, nausea, headache and elevated liver enzymes.
 
Kynamro is produced by Genzyme Corp., of Cambridge, Mass.

© HealthDay

 
1Like our page
2Share
FDA-Approved-Drugs
The FDA has approved a new drug to treat a rare inherited condition in which the body can't remove low-density lipoprotein (LDL) cholesterol from the blood.
Deadly Cholesterol Condition Drug Kynamro
176
2013-37-07
Thursday, 07 Mar 2013 10:37 AM
Newsmax Inc.
 

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved